https://www.youtube.com/watch?v=MbjU8voufmg
Read More
Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
Read More
https://www.benzinga.com/markets/penny-stocks/21/03/20317890/enverics-patient-centric-model-to-enhance-the-quality-of-life-of-cancer-patients
Read More
– Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board – NEW YORK, March 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first…
Read More
https://www.youtube.com/watch?v=TmcwlIcLo9w
Read More
NAPLES, Fla., March 15, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David…
Read More
https://www.pharmaceutical-technology.com/news/enveric-acquires-diverse-molecules/
Read More
https://www.pharmaceutical-business-review.com/news/enveric-biosciences-signs-licensing-agreement-with-diverse-biotech/
Read More
– License has the Potential to Expand Enveric’s Planned Capabilities to Address Cancer Treatment Side Effects – – Innovative Conjugation Platform Aims to Provide Superior Therapeutic Outcomes for Patients by…
Read More
